Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and commercial availability of the RED ...

MIAMI--(BUSINESS WIRE)--Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced U.S. commercial availability of the Penumbra System’s most advanced ...

Launches Indigo ® System Lightning™ 12 in U.S. Appoints Corey L. Teigen, M.D., as Chief Scientific Officer and James F. Benenati, M.D., FSIR, as Chief Medical ...

Offering a new option for physicians to address arterial thrombus removal, the Indigo System Lightning 7 combines the new Indigo System CAT™7 Aspiration Catheter with Lightning Intelligent Aspiration ...

Penumbra, Inc. PEN recently received FDA clearance for the RED 62 Reperfusion Catheter. Following this regulatory go-ahead, the company has also initiated commercial availability of the catheter ...

Penumbra, Inc., a global healthcare company focused on innovative therapies, today announced U.S. commercial availability of the Penumbra System's most advanced technology: Penumbra JET 7 and Penumbra ...

ALAMEDA, Calif. – Penumbra, Inc., a global healthcare company focused on innovative therapies, today announced enrollment of the first patient into the CHEETAH study, a prospective, multi-center U.S.

Now available in the U.S., RED™ 62 is engineered with optimized trackability to help navigate the complex distal vessel anatomy in the brain and deliver powerful aspiration for the removal of blood ...